Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3332090 | Hematology/Oncology Clinics of North America | 2007 | 20 Pages |
Abstract
Breast cancer is the most common neoplasia among women in the world. For the last few years there has been an increasing interest in the development of agents against molecular targets considered to be involved in the process of malignant transformation or tumor progression. Experimental data indicate that various intracellular signaling pathways may be activated or overexpressed in patients who have breast cancer. Targeted therapies against these pathways have recently become one of the most active and promising areas of development in oncology.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Monica Arnedos, Andrew D. Seidman,